Multiple members of The Obesity Society (TOS) unveiled new research about several anti-obesity medications in development at this year's annual meeting of the American Diabetes Association (ADA) held June 23–26.
ADA: Reductions in Body Weight With Retatrutide for Obesity vtcng.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vtcng.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO — Adults with obesity who received the highest dose of a once-weekly injection of retatrutide lost an average of 24.2% of their body weight at 48 weeks compared with placebo, data from a phase 2 study show.
With the highest 12 mg dose of retatrutide (Eli Lilly) — an investigational GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptor agonist
Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair of early studies.